Savara (SVRA) Stock Forecast & Price Target

Savara Inc. has demonstrated strong positive momentum with its molgramostim nebulizer solution, particularly in its Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), which has shown significant improvements in health-related quality of life and exercise capacity across various disease severity subgroups. The company's adjusted sales estimates for its molgramostim product have increased significantly, with anticipated peak annual U.S. sales rising to $962 million, and global peak sales expectations climbing to approximately $1.6 billion as adoption rates exceed those of current off-label uses. Furthermore, the potential pricing for molgramostim has been adjusted upward, with projections now estimating a launch list price of $425,000, supporting an optimistic outlook for revenue generation in the specialty pharmaceuticals segment focused on rare respiratory diseases.

Savara Inc. faces a negative outlook primarily due to anticipated delays in regulatory approval and commercialization of its key product, molgramostim, which are now pushed back to 2028 for the Japanese market, reflecting lowered expectations for market penetration rates. Additionally, higher-than-expected R&D and SG&A expenses, coupled with decreased projections for peak annual royalties from ex-U.S. sales, further undermine the company's financial stability and potential for growth. The ongoing net losses are expected to persist until commercialization, indicating significant financial risks ahead for the company.